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BACKGROUND: Multitarget stool DNA (mt-sDNA) is an approved method for colon cancer 
screening that is especially relevant for patients who cannot undergo colonoscopy. Although the 
test performance has been evaluated in a large clinical trial, it was limited to a predominantly 
white population. Given differences in the epidemiology and biology of colon cancer in African 
American individuals, the authors sought to compare the performance of mt-sDNA between 
racial groups. 
METHODS: The authors prospectively identified patients aged ≥40 years who were referred for 
colonoscopy at an academic medical center and 2 satellite facilities. Prior to the colonoscopy, the 
authors collected stool for mt-sDNA and fecal immunochemical testing (FIT). hey compared 
the sensitivity, specificity, and receiver operating characteristic curve between African American 
and white patients for the detection of advanced lesions or any adenoma. 
RESULTS: A total of 760 patients were included, 34.9% of whom were African American. The 
prevalence of any adenoma (38.9% for African American patients and 33.9% for white patients) 
and that for advanced lesions (6.8% and 6.7%, respectively) were similar between groups. The 
overall sensitivities of mt-sDNA for the detection of advanced lesions and any adenoma were 
43% and 19%, respectively, and the specificities were 91% and 93%, respectively. In general, 
mt-sDNA was more sensitive and less specific than FIT. When stratified by race, the sensitivity, 
specificity, and receiver operating characteristic curve area were similar between African 
American and white patients for both mt-sDNA and FIT.  
CONCLUSIONS: Test performance characteristics of mt-sDNA were comparable in African 
American and white patients. Given the lower uptake of colonoscopy in African American 
individuals, mt-sDNA may offer a promising screening alternative in this patient population. 
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<H1>INTRODUCTION</H1> 
Routine screening for colorectal cancer and adenomatous polyps among adults aged ≥50 years is 
recommended, and approximately 60% of the target population currently is up to date with 
screening, primarily through the use of colonoscopy.1 However, screening rates are consistently 
lower among individuals from lower socioeconomic strata, which is attributed in part to the lack 
of a regular health care provider and health insurance.1 Studies also have reported lower colon 
cancer screening rates among African American ndividuals, which may be attributed in part to 
socioeconomic status2,3 as well as barriers such as fear of the diagnosis, mistrust of the health 
care system, and a lack of provider recommendation. In addition, there a  important differences 
in the biology and clinical behavior of colon cancer in African American individuals compared 
with white individuals, with an earlier age at onset, a greater percentage of right-sided cancers, 
and unique genetic mutations.
 
3,4 
Given the significant number of individuals who are not up to date with colonoscopy reening, 
alternative screening procedures have been developed. These include stool-ba ed tests such as 
fecal immunochemical testing (FIT), radiographic procedures such as computed tomography 
colonography, and other endoscopic procedures such as flexible sigmoidoscopy. Another 
noninvasive testing option is multitarget stool DNA testing (mt-sDNA), which includes a panel 
of methylation markers, oncogenes, and FIT, reduced to a single patient result via an algorithm. 
Although mt-sDNA primarily was designed as a cancer screening test, it also detects a greater 
percentage of advanced, precancerous lesions compared with FIT alone. To the best of our 
knowledge, the largest colorectal cancer screening trial of mt-sDNA to date enrolled nearly 
10,000 participants, 10.7% of whom were African American, but did not stratify results by race 
or ethnicity.5
 
 Thus, we performed a prospective cohort study to evaluate and compare the test 
performance of the commercially available mt-sDNA (Cologuard; Exact Sciences Corporation, 
Madison, Wisconsin) in African American and white individuals. Our goal was to determine 
whether the sensitivity of mt-sDNA in African American patients was comparable to that in 
white patients and thus it is an appropriate screening test in this traditionally underserved patient 
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<H1>MATERIALS AND METHODS</H1> 
The study was conducted from 2012 to 2015 at 3 si es in metropolitan Cleveland, Ohio: 1) an 
urban, tertiary care academic medical center; 2) an affiliated suburban community hospital; and 
3) an affiliated suburban ambulatory surgery center. The methods and results are reported in 
accordance with the STROBE (Strengthening the Reporting of Observational Studies in 
Epidemiology) guidelines.6
 
 Approval for the study was obtained from the University Hospitals 
institutional review board. Patients aged 40 to 80 years who were referred for colonoscopy by 
their health care providers were eligible for enrollment. Patients aged <50 years were largely 
referred because of a family history of colorectal cancer or nonspecific lower gastrointestinal 
symptoms such as constipation. Exclusion criteria were a known history of any malignancy, a 
prior history of adenomatous polyps or serrated neoplasia in the colon, previous colon resection, 
prior colonoscopy within 5 years, overt gastrointestinal bleeding, a diagnosis of ulcerative colitis 
or Crohn disease, or the inability to provide informed consent or understand English. In addition, 
for this analysis, we excluded patients who were of a racial group other than white or African 
American or were of unknown race. 
Prior to undergoing colonoscopy and the bowel preparation, all patients collected stool for mt-
sDNA that was processed according to a standard protocol as well as a commercially available 
FIT (OC-FIT CHEK; Polymedco CDP, LLC, Cortlandt Manor, New York
 
). A questionnaire was 
completed prior to colonoscopy and included health risk factors including height and weight and 
whether the patient ever used tobacco products. Patients then underwent standard colonoscopy; 
the endoscopist was unaware of the mt-sDNA or FIT results but knew that the patient was 
enrolled in the study. All visible lesions were removed or, if not feasible, biopsied, and a positive 
test included findings of ≥1 adenomas, sessile serrated adenomas, or carcinomas. Advanced 
lesions were defined as an adenoma easuring ≥1 cm and/or containing high-grade dysplasia or 
adenocarcinoma. The location of the adenoma was divided into the rectum/rectosigmoid, left 
colon (sigmoid, descending, or splenic flexure), and right colon (transverse, hepatic flexure, 
ascending, or cecum) based on the colonoscopy report. All colonoscopies were performed by 
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Using the findings at colonoscopy as the reference standard, we determined the sensitivity, 
specificity, and area under the receiving operating characteristic (ROC) curve of both mt-sDNA 
and FIT for any adenoma and for advanced lesions. Test characteristics then were compared 
between white and African American patients. 
 
<H1>RESULTS</H1> 
A total of 844 patients agreed to participate in the current study. We excluded 57 patients for the 
following reasons: failure to collect a stool sample prior to colonoscopy (6 atients), patient did 
not keep appointment for colonoscopy (44 patients), and poor preparation at colonoscopy 
without rescheduling (7 patients). For this analysis, we further excluded 27 patients with a self-
identified race other than African American or white (26 patients) or who were of unknown race 
(1 patient), leaving 760 subjects available for analysis. 
 
The mean age of the cohort was 56.7 ± 8.0 years; 60.2% were female and 495 were white 
(65.1%) and 265 were African American (34.9%). Compared with white patients, African 
American individuals were more often female, but there was no difference noted with regard to 
the mean age (Table 1). The average body mass index was higher in African American patients 
and African Americans had a greater prevalence of smoking. O e or more adenomas were found 
in 103 African American patients (38.9%) and 168 white patients (33.9%) (P=.36) and advanced 
lesions, including 2 cancers, were detected in 18 African American patients (6.8%) and 33 white 
patients (6.7%) (P=.12). Among patients with adenomas, there wasa somewhat greater mean 
number of adenomas noted among African Americans. The distribution of adenomas in the colon 
also was similar between the groups and the prevalence of sessile serrated adenomas was 
comparable (Table 1). 
 
Test characteristics of mt-sDNA and FIT for the overall cohort, African American patients, and 
white patients are shown in Table 2. In general, mt-sDNA was more sensitive and less specific 
than FIT for all adenomas as well as advanced lesions. When stratified by race, the sensitivity, 
specificity, and ROC curve area for mt-sDNA were similar between African American d white 
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adenoma). Similarly, the test characteristics for FIT did not differ by racial group (ROC curve 
area for advanced lesions and any adenoma: P=.74 and P=.98, respectively).  
 
There were a total of 40 patients with ≥1 <zaq;4>SSPs in the current study (Table 1). The 
sensitivity of mt-sDNA and FIT were 28% and 2%, respectively, and the corresponding 
specificities were 94% and 98%, respectively. For those SSPs that measured ≥1 cm, the 




Although colorectal cancer is one of the most common causes of cancer mortality in the United 
States, both the incidence and mortality can be reduced through the use of screening with the 
detection of early-stage cancer and the removal of precursor adenomas. African American 
individuals are more likely to be diagnosed with and to die of colorectal cancer than any other 
racial group.3,4,7,8 Moreover, since 1960, although the mortality rate for white individuals has 
declined by 39%, it has increased by 28% in African American individuals.8 The incidence of 
colorectal cancer among African Americans al o remains 15% to 23% higher than in white 
individuals and other racial groups.7 Given the higher colorectal cancer incidence and mortality 
in African American individuals as well as a somewhat lower population-based uptake of 
colonoscopy, the feasibility of alternative screening methods is worthy of investigation. Because 
there may be differences in tumor-related and genetic factors in colorectal cancer affecting 
African American individuals, it is important to identify any differences in the performance 
characteristics of screening tests across racial groups. In the current prospective study, which 
was comprised of one-third African Americans, we found that mt-sDNA testing performed 
equally as well as in other ethnic groups for detecting advanced adenomas or any adenomas. 
These findings, coupled with a previous study that demonstrated comparable test acceptability in 
African American patients and others,9
 
 suggest that mt-sDNA could be an effective approach to 
increasing colorectal cancer screening in African American individuals. In the previous study, 
the most commonly cited reasons for preferring mt-sDNA were the absence of bowel 
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Although to the best of our knowledge s veral studies to date have evaluated the ability of mt-
sDNA to detect adenomas and advanced lesions, few have specifically examined its performance 
among specific racial or ethnic groups. In a prospectiv  study of Alaska natives,10 a population 
with lower access to colonoscopy, the sensitivity and specificity of mt-sDNA for detecting 
advanced lesions were 49% and 91%, respectively, which both were similar to those of a large, 
multicenter study.5 Another recent study examined the uptake of colorectal cancer screening in 
Olmsted County, Minnesota,11
 
 where African American individuals comprise only 3.5% of the 
population. During a 12-month period, the use of both mt-sDNA and colonoscopy were lower in 
African Americans (6.3% and 1.5%, respectively) compared with the general population (8.1% 
and 3.6%, respectively). However, test characteristics were not compared between racial groups. 
Although the current study included a modestly large sample of patients with a substantial 
percentage of African American individuals undergoing age-appropriate screening, we 
acknowledge some limitations. First, this was a single-center study in which patients were 
specifically recruited from a screening population. However, we have no a priori reason to 
question the generalizability of the findings to other centers and regions. Second, the mt-sDNA 
findings were reported as a single, qualitative positive or negative result, which is the reporting 
method in clinical practice. Thus, we were unable to ascertain whether the distribution of 
positive results for specific markers differed between racial groups. Third, both the American 
College of Gastroenterology4 and US Multisociety Task Force on Colorectal Cancer12 guidelines 
recommend the initiation of screening in African American i dividuals at age 45 years. 
However, due to sample size, we did not explicitly evaluate the test performance of mt-sDNA in 
African American patients aged 45 to 50 years. Finally, although colonoscopy was used as the 
reference standard for the calculation of the sensitivity and specificity of mt-sDNA, we recognize 
that it is imperfect and associated with a miss rate for both small and advanced lesions.13
 
 
However, unless the adenoma detection rate at colonoscopy differed systematically between 
African American patients and others, the overall findings should not be biased. The absence of 
differences in lesion detection between white and African American patients also is less likely 
given the similar prevalence of serrated lesions and right-sided adenomas, both of which are 
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The results of the current study demonstrate similar test performance of mt-sDNA in African 
American individuals compared with members of other racial groups, suggesting its feasibility as 
a screening test in this traditionally underserved population. 
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African American individuals have a greater burden of colon cancer with some unique tumor 
mutations, and are less likely to undergo screening. In a prospective clinical study, the authors 
report that the test performance characteristics of multitarget stool DNA testing are similar 
between African American and white patients. 
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